Mendel Money Management Boosts Stock Position in Becton, Dickinson and Company $BDX

Mendel Money Management boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,254 shares of the medical instruments supplier’s stock after purchasing an additional 58 shares during the quarter. Mendel Money Management’s holdings in Becton, Dickinson and Company were worth $388,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of BDX. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock valued at $744,000 after acquiring an additional 748 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock valued at $272,000 after acquiring an additional 53 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Becton, Dickinson and Company by 16.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,847 shares of the medical instruments supplier’s stock valued at $7,928,000 after acquiring an additional 4,906 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Becton, Dickinson and Company by 33.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 61,020 shares of the medical instruments supplier’s stock valued at $13,793,000 after acquiring an additional 15,228 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Trading Down 1.4%

Shares of BDX stock opened at $184.35 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The stock has a fifty day moving average of $189.49 and a two-hundred day moving average of $183.53. The firm has a market capitalization of $52.84 billion, a PE ratio of 33.16, a price-to-earnings-growth ratio of 1.46 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company had revenue of $5.32 billion during the quarter. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Argus upped their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and set a $211.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, October 16th. Finally, Morgan Stanley upped their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $205.40.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares in the company, valued at approximately $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last ninety days, insiders sold 1,895 shares of company stock worth $358,995. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.